Advancing Cancer Treatment
- Assets
- $684.0k
- Revenue
- $3.0m
- Investments
- $0.0
- Employees
- 0
- Location
- Moultonborough, NH
- Founding
- 02/2019
- Data as of
- 12/2022
- EIN
- 83-2886283
Organization Overview
Advancing Cancer Treatment is located in Moultonborough, NH. The organization was established in 2019. According to its NTEE Classification (G12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Advancing Cancer Treatment is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Advancing Cancer Treatment generated $3.0m in total revenue. This organization has experienced exceptional growth, as over the past 4 years, it has increased revenue by an average of 49.4% each year . All expenses for the organization totaled $3.1m during the year ending 12/2022. While expenses have increased by 55.2% per year over the past 4 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2020, Advancing Cancer Treatment has awarded 17 individual grants totaling $962,521. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
ACT'S MISSION IS TO MAKE THE WASHINGTON, DC METROPOLITAN AREA A LEADER IN ADVANCING CLINICAL TRIAL ACCRUAL, THUS ACCELERATING IMPROVED CANCER CARE AND TREATMENT.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ACT'S CURRENT FOCUS IS IMPROVING ACCRUAL TO PROSTATE CANCER CLINICAL TRIALS. ACT'S GOAL IS TO CREATE A PROSTATE REGISTRY AIMED AT GETTING A SIGNIFICANT PORTION OF PROSTATE CANCER PATIENTS TO SIGN UP TO PARTICIPATE BY SUBMITTING A SIMPLE SALIVA TEST THAT WILL PROVIDE THEIR GENETIC INFORMATION FOR RESEARCH, AND PROVIDE AN ALERT SERVICE TO THEM IF ANY TREATMENTS OR THERAPIES MATCH THEIR PROFILE AND COULD HELP CHANGE THEIR OUTCOME.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Otis Brawley Director | Trustee | 0.2 | $0 |
Robert Grossman Director | Trustee | 0.2 | $0 |
Jenny B Aragon-Ching MD Director | Trustee | 0.2 | $0 |
Donald L Trump MD Director | Trustee | 0.2 | $0 |
Adam R Metwalli MD Director | Trustee | 0.2 | $0 |
Pamela Brown Vice President, Secretary | OfficerTrustee | 0.2 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $3,000,000 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $3,000,000 |
| Total Program Service Revenue | $0 |
| Investment income | $10,183 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $3,010,183 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $2,725,416 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $5,600 |
| Fees for services: Accounting | $24,376 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $288,681 |
| Advertising and promotion | $10,500 |
| Office expenses | $2,916 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $6,112 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $2,183 |
| All other expenses | $288 |
| Total functional expenses | $3,103,502 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $682,929 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $1,046 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $683,975 |
| Accounts payable and accrued expenses | $37,428 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $37,428 |
| Net assets without donor restrictions | $646,547 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $683,975 |
Grants Awarded
Over the last fiscal year, Advancing Cancer Treatment has awarded $0 in support to 6 organizations.
| Grant Recipient | Amount |
|---|---|
GEORGIA CORE INC PURPOSE: 110000 | $0 |
JOHNS HOPKINS PURPOSE: 75000 | $0 |
ZERO PURPOSE: 89500 | $0 |
PCEC PURPOSE: 2314266 | $0 |
GUMO FINANCE PURPOSE: 75000 | $0 |
PROSTATE HEALTH ED NETWORK PURPOSE: 45000 | $0 |